This site is intended for healthcare professionals
News

Phase III DERBY and OAKS studies of Empaveli show favourable safety profile in geographic atrophy.- Apellis Pharma

Read time: 1 mins
Published:18th Mar 2022

Apellis Pharmaceuticals announced longer-term data from the Phase III DERBY and OAKS studies of Empaveli (pegcetacoplan), which showed that intravitreal pegcetacoplan, an investigational, targeted C3 therapy, continued to reduce geographic atrophy (GA) lesion growth and demonstrate a favorable safety profile at month 18 for the treatment of GA secondary to age-related macular degeneration (AMD).

In a longer-term analysis of the primary endpoint, pegcetacoplan continued to reduce GA lesion growth compared to pooled sham at month 18 (all p-values are nominal).

In OAKS, pegcetacoplan reduced GA lesion growth with both monthly (22%; p<0.0001) and every-other-month treatment (16%; p="0.0018)." in derby, pegcetacoplan reduced ga lesion growth with both monthly (13%; p="0.0254)" and every-other-month treatment (12%; p="0.0332)." pegcetacoplan demonstrated marked improvements in derby during months 6-12 with reductions of 17% with monthly and 16% with every-other-month treatment compared to months 0-6, and the treatment effects were sustained through month 18. the treatment effects observed in derby were comparable with oaks during months 6-18. data at 18 months from the combined studies show the potential for improving treatment effects with pegcetacoplan over time. the reduction in ga lesion growth improved with monthly pegcetacoplan treatment from 13% to 21% from months 0-6 to months 12-18. the reduction in ga lesion growth improved with every-other-month pegcetacoplan treatment from 12% to 17% from months 0-6 to months 12-18. these data will be included in the new drug application (nda) that the company plans to submit to the fda in the second quarter of 2022.></0.0001)>

Condition: Geographic Atrophy/AMD
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.